Recent News

• 03.11.2025 - Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
• 03.04.2025 - Viking Therapeutics to Participate at Upcoming Investor Conferences
• 02.05.2025 - Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
• 01.29.2025 - Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
• 01.29.2025 - Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
• 01.08.2025 - Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
• 01.06.2025 - Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
• 01.06.2025 - Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

• 03.11.2025 - 8-K Current report
• 03.11.2025 - EX-99.1 EX-99.1
• 02.26.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.05.2025 - EX-99.1 EX-99.1
• 02.05.2025 - 8-K Current report
• 02.04.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2025 - 144 Report of proposed sale of securities